DE69232918D1 - Verwendung von Carbachol zur Behandlung verringerter willkürlicher Mobilität - Google Patents

Verwendung von Carbachol zur Behandlung verringerter willkürlicher Mobilität

Info

Publication number
DE69232918D1
DE69232918D1 DE69232918T DE69232918T DE69232918D1 DE 69232918 D1 DE69232918 D1 DE 69232918D1 DE 69232918 T DE69232918 T DE 69232918T DE 69232918 T DE69232918 T DE 69232918T DE 69232918 D1 DE69232918 D1 DE 69232918D1
Authority
DE
Germany
Prior art keywords
carbachol
treat reduced
mobility
reduced voluntary
voluntary mobility
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69232918T
Other languages
English (en)
Other versions
DE69232918T2 (de
Inventor
Maurizio Santini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69232918D1 publication Critical patent/DE69232918D1/de
Publication of DE69232918T2 publication Critical patent/DE69232918T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69232918T 1991-09-17 1992-09-17 Verwendung von Carbachol zur Behandlung verringerter willkürlicher Mobilität Expired - Lifetime DE69232918T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI912444A IT1251503B (it) 1991-09-17 1991-09-17 Prodotto farmaceutico costituito da un parasimpaticomimetico presentante proprieta' terapeutiche sulla patologia della sensibilita' e della motricita' in genere

Publications (2)

Publication Number Publication Date
DE69232918D1 true DE69232918D1 (de) 2003-03-13
DE69232918T2 DE69232918T2 (de) 2003-12-24

Family

ID=11360674

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69232918T Expired - Lifetime DE69232918T2 (de) 1991-09-17 1992-09-17 Verwendung von Carbachol zur Behandlung verringerter willkürlicher Mobilität

Country Status (5)

Country Link
US (3) US5352698A (de)
EP (1) EP0533639B1 (de)
DE (1) DE69232918T2 (de)
ES (1) ES2191655T3 (de)
IT (1) IT1251503B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100298335A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
US8299079B2 (en) * 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271143A (en) * 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4661509A (en) * 1982-09-28 1987-04-28 Gordon Arnold Z Methods for treating leukopenia
US4857534A (en) * 1984-04-05 1989-08-15 North Carolina State University Method of maintaining ruminants on high energy low fiber diet
US5134121A (en) * 1988-03-28 1992-07-28 Regents Of The University Of California Nerve growth factor peptides
US5084281A (en) * 1989-02-14 1992-01-28 Dillon Richard S Method and solution for treating tissue wounds
US5001117A (en) * 1989-03-07 1991-03-19 Pharmacaps, Inc. Use of lecithin to restore olfaction and taste

Also Published As

Publication number Publication date
US5599836A (en) 1997-02-04
ITMI912444A1 (it) 1993-03-17
EP0533639A1 (de) 1993-03-24
ES2191655T3 (es) 2003-09-16
DE69232918T2 (de) 2003-12-24
ITMI912444A0 (it) 1991-09-17
US5773466A (en) 1998-06-30
EP0533639B1 (de) 2003-02-05
IT1251503B (it) 1995-05-16
US5352698A (en) 1994-10-04

Similar Documents

Publication Publication Date Title
DE69428813D1 (de) Verwendung von Botulinustoxin zur Behandlung von Spannungs-Kopfschmerz
ATE365042T1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE69500089D1 (de) Behandlung von Geflügel
DK0445255T3 (da) Behandling af tilstande og sygdom
DE69312853D1 (de) Behandlung von Gummiartikeln
DE69212620D1 (de) Verwendung von Glycosaminoglycanen zur Behandlung von diabetischer Nephropathie und diabetischer Neuropathie
DE69115921D1 (de) Verfahren zur behandlung und verwendung von abfallstoffen
DE69316203D1 (de) Elektrochemische behandlung von oberflächen
DE69224173D1 (de) Behandlung von lignocellulosischen Materialien
ATE218862T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
DE69215885D1 (de) Behandlung von fleisch
DE69405711D1 (de) Behandlung von rueckstandsoel
DE69221617D1 (de) Aufbereitung von flüssigkeit
DE59202663D1 (de) Verwendung eines UV-Strahlers zur Behandlung von Oberflächen.
DE69331833D1 (de) Verwendung von vitamin d-glykosiden zur behandlung oder prävention von osteoporose
ATE270102T1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE69621447D1 (de) Verwendung von nitroflavonoide zur behandlung von angstzuständen
ATE410181T1 (de) Verwendung von intereferon gamma zur behandlung von herzhypertrophie
ATE209891T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung der seborrhoischen dermatitis
DE59511032D1 (de) Verwendung von notoginsenosid r1 zur behandlung von endotoxinschock oder herzerkrankungen
DE69325141D1 (de) Behandlung von lignozellulosehaltigen Materialien
ATE190486T1 (de) Verwendung von buckminsterfulleren zur behandlung neurotoxischer verletzungen
DE69313261D1 (de) Verwendung von LACTOFERRIN zur Herstellung eines THERAPEUTISCHEN MITTELS zur Behandlung von RHEUMATISMUS
DE69232918D1 (de) Verwendung von Carbachol zur Behandlung verringerter willkürlicher Mobilität
DK99993D0 (da) Treatment and prophylaxis of diseases caused by parasites or bacteria

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 533639

Country of ref document: EP